EXPLORE THE SCIENCE
TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional…
Read article
TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findin…
Read article
TL;DR: A 2026 study in Alzheimer’s & Dementia: Translational Research & Clinical Interventions used lecanemab pharmacokinetic/pharmacodynamic modeling in early Alzheimer’s disease and found that blood biomarkers worsened after treatment stopped, while monthly…
Read article
TL;DR: A 2026 narrative review in the Japanese Journal of Radiology reported that Alzheimer’s brain positron emission tomography (PET) imaging has shifted from supportive diagnosis toward treatment selection because amyloid PET is now central to confirming eli…
Read article
Alzheimer’s Treatment Needs More Than Amyloid TL;DR: A 2026 review in Science China Life Sciences argues that amyloid-beta antibodies such as lecanemab and donanemab are important progress, but Alzheimer’s treatment cannot stop at amyloid. The disease also inv…
Read article
How Lecanemab Clears Brain Amyloid: The Microglia Key TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin…
Read article
Lecanemab shows promise in treating Alzheimer’s disease by reducing clinical deterioration and amyloid-beta plaques, but it has significant adverse effects and requires further research for confirmation. Highlights: FDA Approval: The US FDA authorized lecanema…
Read article
A new drug recently approved for Alzheimer’s disease aims to treat the underlying cause of the condition by removing amyloid plaques in the brain. Though promising, the drug called aducanumab also comes with potential side effects that require careful monitori…
Read article